Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

BACKGROUND AND AIMS: Treatment of hepatitis C virus (HCV) changed dramatically with the introduction of oral direct-acting antiviral drugs due to their high antiviral potency and safety profile. Sofosbuvir plus daclatasvir combination therapy was extensively investigated in HCV genotypes 1, 2, and 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Ossama A, Elsebaey, Mohamed A, Fouad, Mohamed Hassan A, Elashry, Heba, Elshafie, Ahmed I, Elhadidy, Ahmed A, Esheba, Noha E, Elnaggar, Mohammed H, Soliman, Shaimaa, Abd-Elsalam, Sherief
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878661/
https://www.ncbi.nlm.nih.gov/pubmed/29628768
http://dx.doi.org/10.2147/IDR.S160593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878661/
https://www.ncbi.nlm.nih.gov/pubmed/29628768
http://dx.doi.org/10.2147/IDR.S160593

Ejemplares similares